MDT - Medtronic plc

NYSE - NYSE Delayed Price. Currency in USD
119.03
+0.17 (+0.14%)
At close: 4:01PM EST
Stock chart is not supported by your current browser
Previous Close118.86
Open118.95
Bid118.49 x 800
Ask118.98 x 1100
Day's Range118.56 - 119.84
52 Week Range82.77 - 119.84
Volume4,488,998
Avg. Volume4,102,901
Market Cap159.545B
Beta (5Y Monthly)0.60
PE Ratio (TTM)33.81
EPS (TTM)3.52
Earnings DateFeb 17, 2020
Forward Dividend & Yield2.16 (1.82%)
Ex-Dividend DateDec 24, 2019
1y Target Est125.27
  • Moody's

    Allegiance Corporation -- Moody's affirms Cardinal Health's Baa2 senior unsecured rating; outlook changed to negative

    Rating Action: Moody's affirms Cardinal Health's Baa2 senior unsecured rating; outlook changed to negative. Global Credit Research- 17 Jan 2020. New York, January 17, 2020-- Moody's Investors Service affirmed ...

  • Boston Scientific Gets a Boost From New Products, Buyouts
    Zacks

    Boston Scientific Gets a Boost From New Products, Buyouts

    Boston Scientific's (BSX) recent takeovers of BTG, NxThera, Claret Medical, VENITI and Augmenix make us optimistic about their positive synergies to be added to the company portfolio.

  • Diabetes Management Gains FDA Attention: 3 Stocks in Focus
    Zacks

    Diabetes Management Gains FDA Attention: 3 Stocks in Focus

    The FDA recently authorized diabetes care companies to start pairing their medical devices for diabetes management, by combining insulin pumps and glucose monitors.

  • Exact Sciences (EXAS) Provides Q4 Expectations, Stock Falls
    Zacks

    Exact Sciences (EXAS) Provides Q4 Expectations, Stock Falls

    Exact Sciences (EXAS) revenue growth will likely beat expectations for both the fourth quarter and 2019.

  • NuVasive (NUVA) Stock Dips Despite Strong Preliminary Q4 Show
    Zacks

    NuVasive (NUVA) Stock Dips Despite Strong Preliminary Q4 Show

    NuVasive's (NUVA) revenue growth will likely beat expectations for both the fourth quarter and 2019.

  • Globus Medical Gains From International Spine Arm, Innovation
    Zacks

    Globus Medical Gains From International Spine Arm, Innovation

    Globus Medical (GMED) delivers solid spine sales globally. Enabling Technologies too rides high on the rising uptake of ExcelsiusGPS platform.

  • 3 Medical Product Stocks Set to Beat This Earnings Season
    Zacks

    3 Medical Product Stocks Set to Beat This Earnings Season

    Here we discuss three medical product stocks that are due to report soon and are likely to beat estimates on earnings, riding on a host of factors.

  • GlobeNewswire

    Medtronic Recognized with Prestigious Catalyst Award

    DUBLIN, Jan. 16, 2020 (GLOBE NEWSWIRE) --  Medtronic plc (MDT), the global leader in medical technology, has been named one of three recipients of the 2020 Catalyst Award, which recognizes corporations and the groundbreaking initiatives they’ve created to foster an inclusive workplace where women can advance. Medtronic is being recognized for the Medtronic Women’s Network (MWN) and Women in Science and Engineering (WISE) initiatives, key drivers in the company’s overall Inclusion and Diversity strategy. One of five internally established diversity networks within the company, the MWN was refocused by Medtronic CEO Omar Ishrak in 2013 with the idea that diverse perspectives and people produce better decisions, better outcomes and better business performance.

  • GlobeNewswire

    Phoenix Children’s Is the First-Ever Health System in the U.S to Use Medtronic Stealth Autoguide™ Cranial Robotic Guidance Platform for Neurosurgery

    DUBLIN and PHOENIX, Jan. 16, 2020 (GLOBE NEWSWIRE) --  Nationally ranked pediatric leader, Phoenix Children’s Hospital, is the first-ever health system in the U.S. to receive and deploy the newly FDA-cleared Medtronic Stealth Autoguide™ platform. Medtronic, a global leader in medical technology, chose Barrow Neurological Institute (BNI) at Phoenix Children’s as its first partner using this robotic technology. The highly advanced surgical tool is intended for use with the Medtronic StealthStation™ system, and Phoenix Children’s Hospital will use it in surgery for pediatric patients suffering from a range of neurological conditions.

  • Medtronic (MDT) Outpaces Stock Market Gains: What You Should Know
    Zacks

    Medtronic (MDT) Outpaces Stock Market Gains: What You Should Know

    In the latest trading session, Medtronic (MDT) closed at $117.33, marking a +0.25% move from the previous day.

  • Boston Scientific Stock Dips on Dull Preliminary Q4 Results
    Zacks

    Boston Scientific Stock Dips on Dull Preliminary Q4 Results

    Boston Scientific's (BSX) organic revenue growth will likely lag expectations for both the fourth quarter and 2019.

  • LabCorp Hits New 52-Week High: What's Driving the Stock?
    Zacks

    LabCorp Hits New 52-Week High: What's Driving the Stock?

    LabCorp (LH) is optimistic about maintaining its growth momentum on several recent developments.

  • UnitedHealth (UNH) to Post Q4 Earnings: What's in the Cards?
    Zacks

    UnitedHealth (UNH) to Post Q4 Earnings: What's in the Cards?

    UnitedHealth's (UNH) Q4 earnings are likely to have benefited from its operating segments and membership growth.

  • Medtronic's Neurostimulator DBS System Receives CE Mark
    Zacks

    Medtronic's Neurostimulator DBS System Receives CE Mark

    Medtronic's (MDT) Percept PC neurostimulator DBS system, with BrainSense technology, receives the CE Mark, thus clearing the way for the treatment of various neurologic disorders in the EU.

  • GlobeNewswire

    Medtronic Receives CE Mark for InterStim™ Micro Neurostimulator and InterStim™ SureScan™ MRI Leads

    DUBLIN, Jan. 13, 2020 (GLOBE NEWSWIRE) --  Medtronic plc (MDT) today announced it has received CE Mark for its InterStim™ Micro neurostimulator and InterStim™ SureScan™ MRI leads — clearing the technologies for commercial sale and clinical use in Europe. The availability of the new technologies on January 15 will expand access to sacral neuromodulation (SNM) therapy for thousands of potential European patients by offering full-body MRI scan eligible, lifestyle-friendly choices with either the InterStim Micro or InterStim II neurostimulators.

  • 3 Top Blue-Chip Stocks to Buy and Hold Now
    InvestorPlace

    3 Top Blue-Chip Stocks to Buy and Hold Now

    Most investors want big rewards, but not the big risk that can come along with them.Unfortunately, that's not always easy, especially in times of uncertainty. But don't worry. Even in times of chaos, some of the safest stocks to own are blue-chip companies. These are the best-of-the-best in terms of industry leaders. They have a history of growth and returning cash to shareholders. * The Top 15 Stocks to Buy in 2020 In fact, here are three of the top blue-chip stocks to watch in the new year.InvestorPlace - Stock Market News, Stock Advice & Trading Tips Blue-Chip Stocks to Buy: Microsoft (MSFT)Source: The Art of Pics / Shutterstock.com One of the top blue-chip stocks to buy is Microsoft (NASDAQ:MSFT).Up over 55% in the last year, Microsoft has remained a strong investment. In recent months, the company reported first-quarter earnings that beat expectations with earnings per share of $1.38 on sales of $33.1 billion. In the year prior, MSFT earned $1.14 a share on sales of $29.1 billion.The company boosted its quarterly dividend by 11% to 51 cents a share. The board of directors also just approved a new buyback program, authorizing up to $40 billion in share repurchases.And Wedbush analyst Dan Ives just reiterated an "outperform" rating on the stock with a price target of $185, raised from $170 a share. Again, that's thanks to the growth of the company's cloud business."Microsoft remains in an enviable position heading into 2020 on the heels of its cloud success as it continues to fire on all cylinders around its Office 365 and Azure strategic vision," Ives wrote in his research note. He also said customers see "a clear acceleration of larger and more strategic enterprise cloud deals as Redmond is poised to win the majority of the next phase of cloud deployments vs. the likes of Amazon and [Amazon CEO Jeff] Bezos." Apple (AAPL)Source: View Apart / Shutterstock.com Apple (NASDAQ:AAPL) could take a big bite out of 2020.Up 100% in the last year, Apple is still a powerful investment thanks to the coming 5G iPhones and the potential for more buybacks. Analysts at Bank of America and RBC Capital for example just raised their price targets to $330 a share. CFRA analyst Angelo Zino reiterated his "buy" rating with a target of $330.He believes Apple's December quarter results will again beat expectations, "given healthy demand trends for the iPhone 11 as well as improving demand in China."Needham analysts Laura Martin and Dan Medina just raised their price target to $350 from $280 a share. Apple has numerous upside factors. The duo cite its compensation structure, relationships with wealthy consumers and its "gatekeeper" status. * 8 of the Strangest Stocks Worth Your Time In early 2019, Apple boosted its dividend by 5% after increasing it by 16% in 2018.With Apple's strong financials, earnings growth and 5G catalysts, it's unlikely the AAPL stock will go anywhere but up. Medtronic (MDT) Source: JHVEPhoto / Shutterstock.com Over the last year, shares of Medtronic (NYSE:MDT) stock are up 41%.MDT is one of the world's biggest makers of medical devices with more than 4,500 patents. Medtronic is probably one of the safest healthcare stocks on the market, and it has been steadily increasing its dividend for decades. At the moment, MDT pays a dividend yield of 1.9%.Better, earnings remain strong. The company just beat quarterly profit estimates thanks to "strong performance in its unit that makes surgical instruments."Its minimally invasive therapies business saw revenue of $2.14 billion, which was ahead of estimates calling for $2.13 billion. Net sales of $7.71 billion beat estimates for $7.66 billion. And it now expects to post 2020 adjusted profits of $5.57 to $5.63 a share, which is up from a previous forecast for $5.54 to $5.60.Analysts were only looking for 2020 EPS of $5.56.As of this writing, Ian Cooper did not hold a position in any of the aforementioned securities. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * The Top 15 Stocks to Buy in 2020 * The 7 Most Important Companies That Didn't Survive the 2010s * 4 Mega-Tech Stocks Reaching for the Sky The post 3 Top Blue-Chip Stocks to Buy and Hold Now appeared first on InvestorPlace.

  • Teleflex (TFX) Receives FDA Nod for Expanded Use of UroLift
    Zacks

    Teleflex (TFX) Receives FDA Nod for Expanded Use of UroLift

    Teleflex (TFX) receives FDA clearance for expanded indication for the utilization of the UroLift System for treating larger prostrates in men.

  • Benzinga

    The Daily Biotech Pulse: Positive Data Readouts To Spur Aclaris, Moderna And Ultragenyx

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week highs on Jan. 9) Acceleron Pharma Inc (NASDAQ: XLRN ) Allergan plc (NYSE: ...

  • Globus Medical Stock Up on Solid '19 Preliminary Results
    Zacks

    Globus Medical Stock Up on Solid '19 Preliminary Results

    Per Globus Medical (GMED), it ends 2019 on a promising note with an apparently solid robotic pipeline and a speedy competitive recruiting.

  • Benzinga

    The Daily Biotech Pulse: Merck's Keytruda Snags Another FDA Approval, DBV Announces Positive Peanut Allergy Study Findings, Applied Genetic Soars On Trial Results

    The following is a roundup of top developments in the biotech space over the last 24 hours.  Scaling The Peaks (Biotech stocks that hit 52-week highs on Jan. 8.) Allergan plc (NYSE: AGN ):  AbbVie Inc ...

  • GlobeNewswire

    Medtronic Receives CE Mark Approval for the Percept™ PC Neurostimulator DBS System with BrainSense™ Technology

    DUBLIN, Jan. 09, 2020 (GLOBE NEWSWIRE) --  Medtronic plc (MDT) today announced the CE (Conformité Européenne) Mark for Percept™ PC neurostimulator; it is the only Deep Brain Stimulation (DBS) system to be launched in the European Union (EU) with BrainSense™ technology that can sense and record brain signals while delivering therapy to patients with neurologic disorders, such as Parkinson’s disease. BrainSense technology enables physicians to track patient-specific brain signals and correlate these with patient-recorded events, such as symptoms or side-effects associated with their disease or the medications to treat it.

  • Medtronic (MDT) Buys Stimgenics, To Present New Trial Results
    Zacks

    Medtronic (MDT) Buys Stimgenics, To Present New Trial Results

    Medtronic (MDT) acquires Stimgenics to integrate DTM therapy in its pain therapies segment. It will also present trial results favoring the therapy at the upcoming NANS meeting.

  • GlobeNewswire

    Medtronic Acquires Stimgenics, Pioneer of DTM™, a Novel Spinal Cord Stimulation Therapy

    Medtronic plc (MDT) announced it has acquired Stimgenics, LLC, a privately-held company based in Bloomington, Illinois, that has pioneered a novel spinal cord stimulation (SCS) waveform known as Differential Target Multiplexed (DTM™) Spinal Cord Stimulation. The therapy, which is delivered via the Medtronic Intellis™ platform, is a new and unique programming option to treat patients with chronic pain.

  • Abbott's Less-Invasive Surgery for Heart Pump Gets FDA Nod
    Zacks

    Abbott's Less-Invasive Surgery for Heart Pump Gets FDA Nod

    Abbott's (ABT) less invasive approach for heart surgery for its heart pump gets the FDA clearance, thus paving the way for avoiding open heart surgeries.